tbuckley/cabot-search huggingface dataset:
Autologous transplantation for relapsed non-Hodgkin lymphoma using intravenous busulfan and cyclophosphamide as conditioning regimen: A single center experience
Authors: A. Stefanovic, M. P. Escalon, D. L. Pereira, E. S. Santos, M. Goodman, J. J. Byrnes, H. F. Fernandez
Journal: Journal of Clinical Oncology (2007)

18508 Background: High-dose chemotherapy followed by autologous stem cell transplanatation has become standard of care for patients with relapsed, chemosensitive non-Hodgkin’s lymphoma (NHL). In an effort to improve safety and efficacy of this therapeutic approach, new conditioning regimens are being developed. Methods: We retrospectively reviewed the clinical data of 44 consecutive patients with relapsed NHL who had been treated with intravenous Busulfan and Cyclophosphamide (BU/CY) as conditioning regimen for autologous stem cell transplantation between January 2000 and April 2005. Busulfan was administered at a total dose of 3.2 mg/kg on days -7 to -4 (given in two or four divided doses), followed by Cyclophosphamide at a dose of 120 mg/kg intravenously on days -3 and -2. We determined treatment-related morbidity and mortality, event-free survival (EFS, defined as time period between transplantation and occurrence of serious morbidity, disease relapse, disease progression, or death), disease-free survival (DFS), and overall survival (OS). Results: The distribution by histologic type of the 44 patients was as follows: 29 diffuse large B-cell lymphoma, 8 follicular lymphoma, 4 mantle cell lymphoma, and 3 peripheral T-cell lymphoma. Median age was 50 (range 20 to 68 years). At the time of transplantation, 27 patients had attained a complete response (CR or CRu) to salvage chemotherapy, 13 had achieved a partial response, and 4 had stable disease. Median time to neutrophil recovery post transplantation was 11 days. Treatment-related toxicities included nausea/vomiting (77%), diarrhea (43%), and mucositis (66%), which were mild in the majority of cases. Neutropenic fever occurred in 82% of patients. The 100-day mortality rate was 4 (9%) of patients: sepsis (n=1), pneumonia (n=1), and hepatic veno-occlusive disease (n=2). After a median follow-up of 52 months, 3-year Kaplan-Meier estimates of EFS, DFS, and OS were 35%, 41% and 44% respectively. Conclusions: Intravenous BU/CY is a safe and effective conditioning regimen as part of autologous transplantation for relapsed NHL. Our outcomes are comparable to those of other published regimens. Further investigation of this treatment approach is warranted. No significant financial relationships to disclose.
Pneumocystis pneumonia incidence in metastatic solid tumor and lymphoma patients from an administrative health care claims database.
Authors: Margaret Elizabeth McCusker, Jian Huang, Robert Walls
Journal: Journal of Clinical Oncology (2013)

e12500 Background: Pneumoncystis jiroveci pneumonia (PJP) causes severe, often life-threatening illness in immunocompromised patients, including patients with cancer. PJP incidence estimates have been reported for several different cancer types based on case series from single institutions. In order to obtain incidence estimates from a larger pool of patients, we studied PJP claims among patients with metastatic solid tumors (MSTs) or lymphomas in a large administrative healthcare claims database. Methods: Adults diagnosed with MSTs or lymphomas between January 1999-September 2011 were identified in the MarketScan commercial, Medicare supplemental and Medicaid databases based on ICD-9 diagnosis codes. First PJP after cancer diagnosis was defined by PJP ICD-9 code (136.3) associated with an inpatient hospital stay of at least 1 day. Patients with a PJP claim before their cancer diagnosis were excluded. PJP incidence proportions and rates (with 95% CIs) were calculated by age group, sex, HIV status, and tumor type. Results: There were 158 PJP cases (0.04%) among 392,369 HIV-negative MST patients, an incidence rate of 3.0/10,000 pt-yrs (95% CI 2.6-3.5). Incidence rates by metastatic cancer type were 6.8/10,000 pt-yrs for lung, 5.4/10,000 pt-yrs for pancreas, 4.1/10,000 pt-yrs for prostate, 3.0/10,000 pt-yrs for breast, and 0.9/10,000 pt-yrs each for colorectal and ovary. There were 337 PJP cases (0.21%) among 162,799 HIV-negative lymphoma patients, an incidence rate of 9.4/10,000 pt-yrs (95% CI 8.5-10.5). Incidence was higher among males compared to females in both MST and lymphoma patients. PJP incidence rates in HIV-positive patients were approximately 14 times higher than in HIV-negative patients. Conclusions: PJP is a rare occurrence among patients with MSTs or lymphomas. In this analysis of a large administrative healthcare claims database, PJP incidence was higher among lymphoma patients compared to MST patients. Incidence estimates were lower than reports from institutional case series, but patterns of occurrence were consistent in terms of higher incidence in patients with lymphomas or HIV. Differences in incidence by tumor type were also observed among MST patients.
Yield of Clinical Screening for Hypertrophic Cardiomyopathy in Child First-Degree Relatives
Authors: Gabrielle Norrish, Joanna Jager, Ella Field, Ellie Quinn, Hannah Fell, Emma Lord, Marcos N. Cicerchia, Juan Pablo Ochoa, Elena Cervi, Perry M. Elliott, Juan Pablo Kaski
Journal: Circulation (2019)

Hypertrophic cardiomyopathy (HCM) is a heritable myocardial disease with age-related penetrance. Current guidelines recommend clinical screening of relatives beginning at 10 years of age, but the clinical value of this approach has not been systematically evaluated. Anonymized clinical data were collected from children referred for family screening between 1994 and 2017 after diagnosis of HCM in a first-degree relative. Of 1198 consecutive children (≤18 years of age) from 594 families who underwent serial evaluation (median, 3.5 years; interquartile range, 1.2-7), 32 individuals met diagnostic criteria at baseline (median maximal left ventricular wall thickness, 13 mm; interquartile range, 8-21 mm), and 25 additional patients developed HCM during follow-up. Median age at diagnosis was 10 years (interquartile range, 4-13 years); 44 (72%) were ≤12 years of age. Median age of affected patients at the last follow-up was 14 years (interquartile range, 9.5-18.2 years). A family history of childhood HCM was more common in those patients diagnosed with HCM (n=32 [56%] versus n=257 [23%]; P<0.001). Eighteen patients (32%) were started on medication for symptoms; 2 (4%) underwent a septal myectomy; 14 (25%) received an implantable cardioverter-defibrillator; 1 underwent cardiac transplantation; 2 had a resuscitated cardiac arrest; and 1 died after a cerebrovascular accident. Almost 5% of first-degree child relatives undergoing screening meet diagnostic criteria for HCM at first or subsequent evaluations, with the majority presenting as preadolescents; a diagnosis in a child first-degree relative is made in 8% of families screened. The phenotype of familial HCM in childhood is varied and includes severe disease, suggesting that clinical screening should begin at a younger age.
Hybrid scheme with carboplatin and etoposide intravenous (iv) and oral in patients with small cell lung cancer: Should we treat in a different way based on the age?
Authors: Andrea Ruiz-Valdepeñas, Magda Palka, Patricia Ibeas, Bernard Gaston Doger de Speville, Elena Almagro, David Perez Callejo, Miriam Huelves, Ana Lopez-Gonzalez, Constanza Maximiano, Miriam Mendez, Gema Nuevo, Mariano Provencio-Pulla
Journal: Journal of Clinical Oncology (2012)

e17515 Background: The increase in longevity due to a better quality of life in old people makes possible the chemotherapy treatment in the most of patients with Small Cell Lung Cancer. The aim of this research is to evaluate if there are differences in overall survival according to the age (comparing older and younger than 65 years old), in patients treated with the same scheme of chemotherapy. Methods: Patients diagnosed with small cell lung cancer between years 2003 and 2010 and treated in our hospital by the scheme carboplatin 300mg/m 2 IV on day 1, with etoposid 100mg/m 2 per day (iv on day 1 and oral days two to five), were retrospective reviewed to evaluate the overall survival by group of age (older and younger than 65 years old). Results: 96 patients diagnosed of small cell lung cancer were treated in our hospital between 2003 and 2010 with the aforementioned scheme of chemotherapy. 70 of them were on extended stage, and 26 had limited stage; 54 were until 65 years old (56.25%) and 42 were older (43.75%). In extended disease, the elder than 65 presented an overall survival rate one year after the diagnosis of 38.3% (SE 9.3%) and at 18 months 10.2% (SE 6.3%), with a median overall survival of 10 months (Range 1 to 22 months). The younger than sixty five had an overall survival at 12 months of 23.8% (SE 6.6%), and at 18 moths of 5.4 (3.7%), non significant (p:0.437). Their median overall survival was 8.23 months, with a range of &lt;1month to 24 months. In the group with limited stage, the sample older than 65 had a probability of overall survival 1 year after the diagnosis of 46,2% (Standard error (SE), 13.8%), and 23.1% (SE 11.7%) at 18 months, versus a 48.6% (SE 14,8%) at 12 months and 19.4% (SE 12.2%) in younger (p:0.708). The median overall survival in elder than 65 with Limited stage was 11.5 months (6 to 81 months), and for the younger 15 months (range 4 to 25 months). Conclusions: The hybrid scheme carboplatin 300mg/m 2 IV on day 1, with etoposid 100mg/m 2 per day (iv on day 1 and oral days 2 to 5), provides an acceptable overall survival, without significant differences comparing older and younger than 65 years old, both in limited and extended stage.
Abstract 18357: OptoDyCE Improves High-Throughput Cardiotoxicity Detection in Dynamically-Paced Human iPS-CMs Using Voltage-Calcium Recordings
Authors: Aleksandra Klimas, Emilia Entcheva
Journal: Circulation (2017)

Scalability is essential to accelerate development of human stem-cell derived cardiomyocyte- (hiPS-CMs) based models for drug discovery, cardiotoxicity testing, and personalized medicine. All-optic...
Prognostic Value of the Lung Immune Prognostic Index for Patients Treated for Metastatic Non–Small Cell Lung Cancer
Authors: Dickran Kazandjian, Yutao Gong, Patricia Keegan, Richard Pazdur, Gideon M. Blumenthal
Journal: JAMA Oncology (2019)

Previous studies have suggested the importance of the baseline derived neutrophil to lymphocyte ratio (dNLR) and lactate dehydrogenase (LDH) level as prognostic markers. The lung immune prognostic index (LIPI) was shown to be associated with progression-free survival (PFS) and overall survival (OS) among patients with metastatic non-small cell lung cancer (mNSCLC) treated with immune checkpoint inhibitors (ICIs) but not cytotoxic chemotherapy (CCT).To determine whether the LIPI is associated with long-term outcomes in pooled analyses of clinical studies of ICI and targeted therapy (TT) for patients with mNSCLC.An exploratory pooled analysis was performed of the LIPI on data from 11 randomized clinical multinational trials evaluating ICIs and TT submitted to the US Food and Drug Administration between January 1, 2013, and December 31, 2017, for 4914 patients with mNSCLC. Lung immune prognostic index scores were calculated based on the dNLR and the LDH level per previous publications to generate good, intermediate, and poor composite scores. Multivariable Cox proportional PFS and OS hazard ratios were generated for the dNLR, the LDH level, age, smoking status, histologic characteristics, and Eastern Cooperative Oncology Group performance score.Overall survival and PFS and their association with good, intermediate, or poor prognostic LIPI scores.Eleven mNSCLC randomized trials were analyzed, including 3987 patients with available data. In 5 ICI trials comprising 2440 patients, 1368 patients received ICIs and 1072 patients received CCT. In 6 TT trials comprising 1547 patients, 1110 patients received TT and 437 patients received CCT. A good LIPI score was associated with better OS among patients receiving ICIs (hazard ratio, 0.34; 95% CI, 0.28-0.42), TT (hazard ratio, 0.28; 95% CI, 0.21-0.37), and CCT (hazard ratio, 0.49; 95% CI, 0.40-0.60 in ICI trials; hazard ratio, 0.41; 95% CI, 0.27-0.61 in TT trials) than those with poor LIPI scores. Similar findings were observed in terms of PFS (ICIs: hazard ratio, 0.59; 95% CI, 0.48-0.72; TT: hazard ratio, 0.46; 95% CI, 0.37-0.57; and CCT: hazard ratio, 0.56; 95% CI, 0.45-0.68 in ICI trials; hazard ratio, 0.51; 95% CI, 0.38-0.69 in TT trials).The baseline LDH level and dNLR are important prognostic biomarkers irrespective of treatment modality for patients with mNSCLC. As further prospective clinical trial information is collected, the role of the LIPI score can be better defined.
CAR T Cell Relapse CD19 Negative ALL Cells Express Integrins and Integrin Blockade Can Prolong Survival In Vivo
Authors: Hye Na Kim, Solah Lee, Kristen Fousek, Shuangyue Li, Anne Kim, Junji Watanabe, Halvard Bonig, Nabil Ahmed, Hisham Abdel-Azim, Nora Heisterkamp, Yong-Mi Kim
Journal: Blood (2017)
Diffusion weighted MR imaging versus F18 FDG PETC CT in identifying small hepatic metastases.
Authors: Mallarajapatna Govindarajan, Kanakapura Ramanna Nagaraj, Kumar G Kallur, Gothlu Ramachandra Prashanth, Swamy Shivakumar, S Sudhakar, Krishnappa Rajkumar, Desai Indresh, P S Sridhar, Basavalinga S. Ajaikumar
Journal: Journal of Clinical Oncology (2012)

e14675 Background: This exploratory study assessed the ability of diffusion weighted MRI imaging in identifying small liver metastases as compared to F18- FDG PETCT. Methods: Patients with diagnosis of carcinoma of breast, lung, colorectal, pancreas, neuroendocrine and HCC who were staged for their disease using PET CT and MRI were included in the study. We randomly analyzed and compared PETCT and MRI images of 40 patients with hepatic metastases for sensitivity in detection of metastatic lesions in the liver on PETCT and MRI. Where possible, biopsy was performed if MRI/PET CT showed one or two small lesions in the liver. We performed ANCOVA to detect differences between PETCT and MRI controlling for primary sites of disease as a covariate. Results: The mean number of small lesions detected on PETCT was 0.92 where as it was 3.96 in MRI. There was a significant increase in small (p=0.02) and total number of lesions (p=0.01) seen on MRI compared to PET CT but not in large lesions. MRI was able to detect subcentimeter lesions more accurately than PET CT. Random biopsies done on small lesions found on MRI were positive for disease. MRI was able to detect small subcentimeter lesions three times more accurately than PET CT. Conclusions: MR diffusion is more sensitive in indentifying subcentimeter metastatic deposits in the liver that could help in accurate staging when PET CT is negative for liver metastases or when locoregional treatment for oligometastases is contemplated. However, pixels of DWI MRI (like reduced Signal to noise ratio at high b value, artefacts at liver edges and left lobe due to exaggerated susceptibility weighting and spin dephasing) need to be addressed by using other morphological images.
The Ethics of Public and Service User Involvement in Health Research: The Need for Participatory Reflection on Everyday Ethical Issues
Authors: Tineke Abma, Barbara Groot, Guy Widdershoven
Journal: The American Journal of Bioethics (2019)

(2019). The Ethics of Public and Service User Involvement in Health Research: The Need for Participatory Reflection on Everyday Ethical Issues. The American Journal of Bioethics: Vol. 19, No. 8, pp. 23-25.
Prognostic impact of FHIT, APC, and HER2 status in resected gastric cancer: A clinical-biological risk stratification model.
Authors: Emilio Bria, Stefano Barbi, Giovanni De Manzoni, Stefania Beghelli, Anna Tomezzoli, Melissa Frizziero, Isabella Sperduti, Samantha Bersani, Giampaolo Tortora, Aldo Scarpa
Journal: Journal of Clinical Oncology (2012)

4076 Background: The dismal prognosis of gastric cancer prompts for the identification of factors predictive of survival/response to treatment. The potential prognostic value of 11 molecular markers was investigated in a retrospective series of 208 resected gastric cancers. Methods: Molecular/clinicopathological data were correlated to cancer-specific/overall survival (CSS/OS) using a Cox model. Molecular data were: microsatellite instability, CDX2, APC, ß-catenin, E-Cadherin, FHIT, P53, p21, HER-2 (IHC/FISH), TOPO2A amplification (FISH) e PIK3CA mutation (exons 9/20). ROC analysis provided optimal cut-offs and model validation. A logistic equation with regression analysis coefficients was constructed to estimate individual patients’ probability (IPP) of death. Internal cross-validation (100 simulations, 80% of the dataset) was accomplished. Multivariate model Ratios served to derive a prognostic continuous score to identify risk classes. Results: 208 patients were studied (median follow-up 16 months, range 1-155). Multivariate analysis selected 8 independent CSS predictors: sex (HR 1.53, p=0.04), stage (HR 5.40, p&lt;0.0001), R (HR 2.69, p&lt;0.0001), localization (HR 1.64, p=0.008), LN (HR 1.55, p=0.02), APC (HR 1.91, p=0.001), FHIT (HR 1.54, p=0.05) and HER-2 (HR 1.92, p=0.08). Independent OS predictors were: sex, age, stage, R, localization, LN, APC and HER-2. Cross-validation analysis confirmed APC, FHIT and HER-2 as the biological variables displaying significant correlation with CSS (replication: 98%, 51%, 31%). The multivariate model predicted a 2-yr IPP of cancer-death/death with a prognostic accuracy of 0.87 (SE 0.02)/0.91 (SE 0.02). A 2-class risk stratification model was developed with the ROC generated cut-off prognostic score (AUC 0.87, SE 0.03; Sensitivity 85.3%, Specificity 78.9%); see table below. This 2-class model has a prognostic performance for CSS/OS of 0.82 (SE 0.03)/0.81 (SE 0.02). Conclusions: FHIT, APC and HER-2 represent powerful prognostic factors for resected GC and may complement clinical parameters to accurately predict individual patient risk. [Table: see text]
Reply to Lipworth and Kuo: Resistance Heterogeneity and Small Airway Asthma Phenotype
Authors: Salman Siddiqui
Journal: American Journal of Respiratory and Critical Care Medicine (2019)

To further put these changes into clinical context, we previously measured IOS in response to propranolol-induced bronchoconstriction in patients with asthma where there was a 0.05 (kPa/L) $ s increase in R5 2 R20 corresponding to a 104.1% (95% CI, 22.6 to 185.6%) change, along with a subsequent bronchodilator response to salbutamol of 20.17 (kPa/L) $ s and 2115.6%(95% CI, 255.6% to 2175.7%), respectively (2).Moreover, in a health informatics evaluation of 302 patients with asthma, there was a 45% increased risk for worse control in relation to oral corticosteroid use, and 47% in relation to inhaled albuterol use measured during a 2-year period when comparing cohorts of patients with asthma, using a cutoff value for R5 2 R20 of less than or greater than 0.07 (kPa/L) $ s (3).Hence, the small airway asthma phenotype reflected by abnormal R5 2 R20 is associated with poorer control.We believe the findings of Foy and colleagues (1) are important in further validating the use of IOS in determining effects of treatments on small airways of patients with asthma.
Reassessment of the prevalence of soil-transmitted helminth infections in Sri Lanka to enable a more focused control programme: a cross-sectional national school survey with spatial modelling
Authors: Dileepa Senajith Ediriweera, Sharmini Gunawardena, Nipul Kithsiri Gunawardena, Devika Iddawela, Selvam Kannathasan, Arumugam Murugananthan, Channa Yahathugoda, Arunasalam Pathmeswaran, Peter John Diggle, Nilanthi de Silva
Journal: The Lancet Global Health (2019)

In Sri Lanka, deworming programmes for soil-transmitted helminth infections became an integral part of school health in the 1960s, whereas routine antenatal deworming with mebendazole started in the 1980s. A 2003 national soil-transmitted helminth survey done among schoolchildren found an overall prevalence of 6·9%. In our study, we aimed to reassess the national prevalence of soil-transmitted helminth infections to enable implementation of a more focused control programme that targets smaller administrative areas at risk of continued transmission.
Response to Comment on Braffett et al. Association of Insulin Dose, Cardiometabolic Risk Factors, and Cardiovascular Disease in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study. Diabetes Care 2019;42:657–664
Authors: Barbara H. Braffett, Samuel Dagogo-Jack, Ionut Bebu, William I. Sivitz, Mary Larkin, Orville Kolterman, John M. Lachin
Journal: Diabetes Care (2019)

Snaith et al. (1) suggest that the relationship between insulin dose and adverse cardiometabolic profile might be mediated by insulin resistance and cite data linking clamp-derived measurement of insulin resistance and coronary artery calcification (2). We do not have any direct assessment of insulin resistance in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study; however, the association among weight gain, insulin resistance, and adverse …
Wearable sensors for monitoring the physiological and biochemical profile of the athlete
Authors: Dhruv R. Seshadri, Ryan T. Li, James E. Voos, James R. Rowbottom, Celeste M. Alfes, Christian A. Zorman, Colin K. Drummond
Journal: npj Digital Medicine (2019)

Abstract Athletes are continually seeking new technologies and therapies to gain a competitive edge to maximize their health and performance. Athletes have gravitated toward the use of wearable sensors to monitor their training and recovery. Wearable technologies currently utilized by sports teams monitor both the internal and external workload of athletes. However, there remains an unmet medical need by the sports community to gain further insight into the internal workload of the athlete to tailor recovery protocols to each athlete. The ability to monitor biomarkers from saliva or sweat in a noninvasive and continuous manner remain the next technological gap for sports medical personnel to tailor hydration and recovery protocols per the athlete. The emergence of flexible and stretchable electronics coupled with the ability to quantify biochemical analytes and physiological parameters have enabled the detection of key markers indicative of performance and stress, as reviewed in this paper.
Multinutrient Supplementation for Prevention of Major Depressive Disorder in Overweight Adults—Reply
Authors: Ingeborg A. Brouwer, Brenda W. H. J. Penninx, Marjolein Visser
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal